Valeant Pharmaceuticals’ price spikes aren’t isolated to four drugs, but is the company’s business model, a top senator said Wednesday.
The drugmaker was contrite about raising the price of four drugs by in some cases up to 6,000 percent, with the outgoing CEO telling a Senate panel that the company was too aggressive.
Real journalism.Trusted by millions.
Unlimited access to in-depth reporting, expert analysis, and the stories that shape our country.
Subscribe Now
Already a member? Log in
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.